FDA inspection
Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company: FDA inspection ending Sep 11, 2017
FDA inspection 1030016 · Voluntary Action Indicated (VAI) · Manati, PR
Key facts
| Inspection ID | 1030016 |
|---|---|
| Firm | Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company |
| FEI number | 2650089 |
| Address | Rd # 686, Km # 2.3, Sector Cotto Norte, Bo. Tierras Nuevas |
| City | Manati |
| State | PR |
| ZIP | 00674 |
| Country | United States |
| Fiscal year | 2017 |
| Inspection end date | Sep 11, 2017 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data